| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Mebendazole is an Antihelminthic. Mebendazole is a benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth.
| ln Vitro |
With an IC50 value of 0.24 μM, mebendazole (1 nM-0.1 mM; 72 h) inhibits GL261 tumor neural cells [1]. 0.1 μM and 1 μM mebendazole for 24 hours causes 060919 pleomorphic astrocyte disruption. Mebendazole (10 nM–10 μM; 48 h) suppresses microtubule polymerization and microtubule structure in tumor (GBM) cells, inhibits Hh signaling, and reduces downstream Hh protein expression. It also regulates Hh protein expression by lowering Gli1 in tumor tissues [1]. Gli1 expression is inhibited by metronidazole, with an IC50 value of 516 nM[2]. Human medulloblastoma tumor cells with constitutive Hh activation exhibit reduced expression and blocked primary cilia development when exposed to mebendazole (10 nM-10 μM; 48 h). Additive suppression of normal Hh signaling is achieved when mebendazole and vismodegib are combined [2]. In a therapeutic environment, mebendazole has been demonstrated to be successful in treating severe cases of CNS echinococcosis. fluorescent imaging [1]
|
|---|---|
| ln Vivo |
Mebendazole (50 mg/kg; oral; once daily for the first 20 days, five days a week, two days off; 45 days) was administered to both the human pleomorphic blastoma (GBM) xenograft 060919 and the syngeneic GL261 mouse model.
|
| Cell Assay |
Immunofluorescence [1]
Cell Types: Glioblastoma multiforme (GBM) 060919 Cell Tested Concentrations: 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: The microtubule structure is destroyed. System penetration characteristics [3]. Immunofluorescence [2] Cell Types: DAOY and hTERT-RPE1 Cell Tested Concentrations: 0, 0.1, 0.5, 0.75 and 1 μM Incubation Duration: 12 hrs (hours) Experimental Results: GLI1 protein levels diminished and caspase-3 protein levels increased cleavage. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice (5-6 weeks old) implanted with GL261 glioma cells and 060919 human glioblastoma multiforme (GBM) [1]
Doses: 50 mg/kg; Inhibition in mouse model Intracranial tumor growth [1]. Use 50% (v/v) sesame oil and PBS[2] Route of Administration: po (oral gavage); starting 5 days after tumor implantation, daily dose of 50 mg/kg for the first 20 days of treatment, then changing to 50 mg/kg, Lasts 5 days, with 2 days off per week. Experimental Results: In the syngeneic GL261 mouse model, mean survival increased to 49 days compared with 30 days in controls. Mean survival was extended to 65 days compared with 48 days of controls in the 060919 human glioblastoma multiforme (GBM) xenograft mouse model. |
| References |
[1]. Bai RY, et al. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011 Sep;13(9):974-82.
[2]. Larsen AR, et al. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Mol Cancer Ther. 2015 Jan;14(1):3-13. [3]. Erdinçler P, et al. The role of mebendazole in the surgical treatment of central nervous system hydatid disease. Br J Neurosurg. 1997 Apr;11(2):116-20. |
| Molecular Formula |
C16H13N3O3
|
|---|---|
| Molecular Weight |
295.3
|
| Exact Mass |
295.09569
|
| CAS # |
31431-39-7
|
| Related CAS # |
Mebendazole-d3;1173021-87-8
|
| SMILES |
O=C(OC)NC1=NC2=CC=C(C(C3=CC=CC=C3)=O)C=C2N1
|
| InChi Key |
OPXLLQIJSORQAM-UHFFFAOYSA-N InChi Code
|
| Chemical Name |
methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate
|
| Synonyms |
Mebendazole Vermox Telmin Pantelmin Mebenvet Telmin Vermicol Vermidil Vermin Vermox Wormkuur
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~4.17 mg/mL (~14.12 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.42 mg/mL (1.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 4.2 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.42 mg/mL (1.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 4.2 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.42 mg/mL (1.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3864 mL | 16.9319 mL | 33.8639 mL | |
| 5 mM | 0.6773 mL | 3.3864 mL | 6.7728 mL | |
| 10 mM | 0.3386 mL | 1.6932 mL | 3.3864 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA